During the course of evaluating the podcasts, I came across a number of issues that podcasters were running into. Issues that can make the difference between attracting the right target audience, or driving them away
Mistakes Life Science Podcasters Make Read More »
What value can Design Thinking and User Experience design principles bring to drug discovery?
Why UX Matters In Drug Discovery Read More »
Learn how you can use podcasts to keep up to date in areas like genomics, bioinformatics, cancer research, drug discovery and drug development.
At the front end of most drug discovery programs lies a step called Target Identification, and a few months ago I sat down with a colleague to discuss their approach to target identification. In particular, “how do you characterize a target”? I was surprised at how much that process can vary from company to company. As
Drug Target Identification: And then a miracle occurs Read More »
One of the key challenges for bioinformaticians in this age is extracting meaningful findings from abstracts and full text articles. Text mining solutions can only take it so far, and previous comparative studies have shown that Amazon Mechanical Turk solutions and automated text mining solutions have similar levels of success when it comes to identifying terms
Tinkering With Semantic Markup Read More »
Part of what makes user group meetings so interesting is getting the opportunity to peek behind the curtains and see someone else’s operation. In last night’s, KNIME user group meeting, Brock Luty of Dart NeuroScience gave an interesting perspective on Dart’s cheminformatics computing stack used to support parallel synthesis (chemical library design): OpenEye for predictive
KNIME and Cheminformatics: A Peek Behind The Curtain Read More »
One of the things that I’m always curious about, is the effect of a sequence variation on the conformation of a target. Recently I wrote about ClinVar and SwissVar, two tools for examining variants and their associations with disease. Since the PDB tends to have either wild type versions of a protein, or versions of
SwissModel: It’s not what you think Read More »
The intertubes have been abuzz lately with the news of Merrimack’s results from their Phase III trial of a new triplet therapy for pancreatic cancer. The triplet combines older standard of care drugs like 5FU and leucovorin with their new compound MM-398. The trial also compares MM-398 directly against 5FU and leucovorin. The drug, which
Merrimack’s New Pancreatic Cancer Drug Read More »
This week Brock Luty of Dart Neuroscience hosted the first San Diego KNIME User Group meeting. Michael Berthold, one of the founders of KNIME, came down from San Francisco to deliver a briefing Mark Donnelly of XIFIN demonstrated how a business that had formerly been run on a series of linked spreadsheets, was able to
Notes from San Diego KNIME User Group Meeting Read More »
A recent announcement at the AACRs-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19–23, points to some promising results in recent trials that targeted multiple pathways downstream of KRAS (including PI3K/AKT, RAF/MEK/ERK and RAL). The studies conducted by Barry Nelkin at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins involved pre-clinical
Promising Preclinical Results in Pancreatic Cancer Read More »
